KENYATTE CANIDATE: Open Payments
NPI 1427562701 · HARRISBURG, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,188 in 171 payments from 10 companies in 2025. Trend: 2023 $692 · 2024 $3,351 · 2025 $3,188
Food & beverage: $3,077Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 43 | $895 |
| Neurocrine BioSciences, Inc. | 25 | $416 |
| Alkermes, Inc. | 24 | $406 |
| E.R. Squibb & Sons, L.L.C. | 19 | $341 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $304 |
| ABBVIE INC. | 15 | $294 |
| Janssen Pharmaceuticals, Inc | 8 | $179 |
| Axsome Therapeutics, Inc. | 10 | $160 |
| Otsuka America Pharmaceutical, Inc. | 8 | $151 |
| Lundbeck LLC | 3 | $44 |
Products named: UZEDY, INGREZZA, LYBALVI, AUSTEDO XR, COBENFY, CAPLYTA, VRAYLAR, REXULTI.
Industry payments across PA — which companies pay providers there.
